Evidence map›Paper›PMID 42125647›Full record

ArticlePhysics and imaging in radiation oncology2026

Estimation of accumulated dose to organs at risk in head and neck cancer patients treated with scheduled replanning and dose painting in the ARTFORCE trial.

Anna Liza M P de Leeuw, Simon R van Kranen, Jordi Giralt, Yungan Tao, Sergi Benavente, Thanh-Vân F Nguyen, Frank J P Hoebers, Ann Hoeben, Chris H J Terhaard, Lip Wai Lee and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anna Liza M P de LeeuwDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Simon R van KranenDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jordi GiraltDepartment of Radiation Oncology, Hospital General Vall d'Hebron, Barcelona, Spain.
Yungan TaoDepartment of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
Sergi BenaventeDepartment of Radiation Oncology, Hospital General Vall d'Hebron, Barcelona, Spain.
Thanh-Vân F NguyenDepartment of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
Frank J P HoebersDepartment of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Ann HoebenDivision of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology Maastricht University Medical Center+, Maastricht, the Netherlands.
Chris H J TerhaardDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Lip Wai LeeDepartment of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Signe FrieslandDepartment of Oncology and Pathology, Karolinska Institutet, Department of Head, Neck, Lung and Skin Tumors, Karolinska University Hospital, Stockholm, Sweden.
Roel J H M SteenbakkersDepartment of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands.
Harry BartelinkDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Coen R N RaschDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Jan-Jakob SonkeDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Olga Hamming-VriezeDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: This study investigated whether scheduled adaptive radiotherapy (ART) improved delivered dose to organs at risk (OAR) in patients with locally advanced head and neck cancer treated with dose painting (DP). Materials and methods: Delivered doses were estimated for 81 patients who were prospectively treated with DP + ART using deformable image registration between CBCT and the planning CT's. Three simulations were conducted, evaluating (1) a scenario without replanning (Sim Results: In Sim Conclusions: Although relevant dose differences between planned and delivered doses were seen in almost half of the patients without ART, minimal improvements in delivered doses were seen introducing ART. Nonetheless, Df10 was prognostic for relevant changes upon completing treatment and selecting patients for ART significantly improved larynx dose. Incorporating accumulated dose into patient selection for ART could help avoid unforeseen increases in delivered dose.

Indexed as

Adaptive radiotherapyDose paintingHead and neck cancerReplanning

Identifiers

PMID42125647
PMCPMC13158767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.